Dashboard
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Poor long term growth as Net Sales has grown by an annual rate of 19.82% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.11
2
Flat results in Jan 25
3
Risky - Negative EBITDA
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CAD 2 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.60
98.83%
-0.52
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jan 2025)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-50.0%
0%
-50.0%
6 Months
-50.0%
0%
-50.0%
1 Year
-66.67%
0%
-66.67%
2 Years
0%
0%
0.0%
3 Years
-66.67%
0%
-66.67%
4 Years
-94.44%
0%
-94.44%
5 Years
-90.91%
0%
-90.91%
Aion Therapeutic, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.82%
EBIT Growth (5y)
-6.48%
EBIT to Interest (avg)
-1.11
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
-0.42
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.52
EV to EBIT
-3.29
EV to EBITDA
-3.57
EV to Capital Employed
-2.78
EV to Sales
3.54
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jan'25 - YoY
Jan'25
Jan'24
Change(%)
Net Sales
0.50
0.20
150.00%
Operating Profit (PBDIT) excl Other Income
-0.20
-0.20
Interest
0.20
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.30
-0.40
25.00%
Operating Profit Margin (Excl OI)
-440.50%
-1,077.40%
63.69%
USD in Million.
Net Sales
YoY Growth in quarter ended Jan 2025 is 150.00% vs 0.00% in Jan 2024
Consolidated Net Profit
YoY Growth in quarter ended Jan 2025 is 25.00% vs -100.00% in Jan 2024
Annual Results Snapshot (Consolidated) - Apr'24
Apr'24
Apr'23
Change(%)
Net Sales
0.40
0.00
Operating Profit (PBDIT) excl Other Income
-1.10
-1.00
-10.00%
Interest
0.20
0.10
100.00%
Exceptional Items
-2.00
0.70
-385.71%
Consolidate Net Profit
-6.30
-0.30
-2,000.00%
Operating Profit Margin (Excl OI)
-3,240.90%
0.00%
-324.09%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2024 is 0.00% vs 0.00% in Apr 2023
Consolidated Net Profit
YoY Growth in year ended Apr 2024 is -2,000.00% vs 92.11% in Apr 2023
About Aion Therapeutic, Inc. 
Aion Therapeutic, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






